Record Full-Year Revenue and Exceptional Growth
Total revenue for FY2025 was $92.4 million, a 480% year-over-year increase driven primarily by IM8.
Fourth Quarter Surge
Q4 2025 revenue was $36.6 million, up 457% year-over-year and 55% sequentially; IM8 contributed $27.4 million in Q4.
IM8 Rapid Scale and Run Rate
IM8 reached a $120 million annualized revenue run rate in under 12 months and generated $60.1 million in revenue for FY2025, with 40% of IM8 revenue from the U.S. and presence across ~30 international markets.
Strong Gross Profit and Margins
Q4 gross profit grew ~804% YoY to $21.7 million with a consolidated gross margin of 59%; FY2025 gross profit was $48.9 million, up ~428% YoY. IM8 delivered a ~63% gross margin.
Improving Adjusted EBITDA Trends (2025)
Q4 adjusted EBITDA loss was $2.3 million, a 70.4% improvement YoY; full-year adjusted EBITDA loss improved 27% to $13 million versus prior year, indicating operating leverage as scale increases.
Robust Balance Sheet and Divestitures
As of Feb 15, 2026, Prenetics reported approximately $171.1 million in total adjusted liquid assets, zero debt. 2025–early-2026 divestitures included ACT Genomics ($72M sale with $46M cash), Europa (all-stock $30M), and a 35% stake in Insighta sold to Tencent for $70M (received $69M).
Strong Unit Economics and Subscription Metrics
Blended LTV:CAC is projected at ~3x; payback period for 2025 was ~3.4 months. New customer blended average order value rose from $110 in 2025 to ~$233 in early 2026 (~112% increase) after introducing quarterly subscriptions; new customer subscription rate ~80%.
Clear 2026 Guidance and Path to Profitability
Company reaffirmed IM8 revenue guidance of ~$180M–$200M for FY2026 (~300% YoY growth), targeting ~60% gross margin for 2026 and a path to adjusted EBITDA profitability by Q4 2027.
Operational and Marketing Efficiency via AI
Heavy use of AI in marketing/testing: rolling out ~800–1,000 new ads weekly with algorithmic optimization and an AI-driven Instagram video that reached 233 million views, supporting efficient top-of-funnel acquisition.
Third-Party Validation
Research coverage initiated by ROTH Capital and Sidoti & Company with buy ratings and 12-month price targets of $36 and $30, respectively.